Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2455-2461

  Rancourt, Claudine ^a,c   Rogers, Buck E ^a   Sosnowski, Barbara A ^b   Wang, Minghui ^a   Piché, Alain ^a,c   Pierce, Glenn F ^b   Alvarez, Ronald D ^a   Siegal, Gene P ^a   Douglas, Joanne T ^a   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Prizm Pharmaceuticals Inc   (United States)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; FEMALE; GENE TARGETING; GENE TRANSFER; HORMONE ACTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; VIRUS GENE;

ADENOVIRIDAE; ANIMALS; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE THERAPY; HUMANS; MICE; MICE, SCID; OVARIAN NEOPLASMS; SIMPLEXVIRUS; SURVIVAL RATE; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0031755915     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
2. Hirschowitz, E., Ohwada, A., Pasca, W., Russi, T., and Crystal, R. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther., 6: 1055-1063, 1995.
3. Sorscher, E. J., Peng, S., Bebok, Z., Allan, P. W., Bennett, J., Lee, L., and Parker, W. B. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther., 1: 233-238, 1994.
4. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst., 89: 21-39, 1997.
5. Ross, G., Erickson, R., Knorr, D., Motulsky, A. G., Parkman, R., Samulski, J., Straus, S. E., and Smith, B. R. Gene therapy in the United States: a five-year status report. Hum. Gene Ther., 7: 1781-1790, 1996.
6. Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gonczol, E., and Wilson, J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA, 91: 4407-4411, 1994.
7. Yang, Y., Li, Q., Ertl, H. C., and Wilson, J. M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol., 69: 2004-2015, 1995.
8. Sterman, D. H., Treat, J., Elshami, A. A., Amin, K., Molnar-Kimber, K., Coonrod, L. E., Recio, A., Wilson, J. M., Roberts, J. R., Litzky, L. A., Albelda, S. M., and Kaiser, L. R. A phase I clinical trial of adenoviral-mediated herpes simplex virus thymidine kinase gene therapy for malignant mesothelioma: preliminary results. Cancer Gene Ther., 4: S29, 1996.
9. Crystal, R. G., McElvaney, N. G., Rosenfeld, M. A., Chu, C. S., Mastrangeli, A., Hay, J. G., Brody, S. L., Jaffe, H. A., Eissa, N. T., and Danel, C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis [see comments]. Nat. Genet., 8: 42-51, 1994.
10. Schulick, A. H., Dong, G., Newman, K. D., Virmani, R., and Dichek, D. A. Endothelium-specific in vivo gene transfer. Circ. Res., 77: 475-485, 1995.
11. Schulick, A. H., Newman, K. D., Virmani, R., and Dichek, D. A. In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity. Circulation, 91: 2407-2414, 1995.
12. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol., 14: 1574-1578, 1996.
13. Goldman, C. K., Rogers, B. E., Douglas, J. T., Sosnowski, B. A., Ying, W., Siegal, G. P., Baird, A., Campain, J. A., and Curiel, D. T. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res., 57: 1447-1451, 1997.
14. Rogers, B. E., Douglas, J. T., Sosnowski, B. A., Ying, W., Pierce, G., Buschbaum, D. J., DellaManna, D., Baird, A., and Curiel, D. T. Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector. Tumor Targeting, 3: 25-31, 1998.
15. Graham, F., Smiley, J., Russell, W., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-72, 1977.
16. Herz, J., and Gerard, R. D. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA, 90: 2812-2816, 1993.
17. Rosenfeld, M. E., Feng. M., Michael, S. I., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin. Cancer Res., 1: 1571-1580, 1995.
18. Graham, F., and Prevec, L. Manipulation of adenovirus vectors. In: E. J. Murray and J. M. Walker (eds.). Methods in Molecular Biology, Vol. 7. Gene transfer and expression techniques, pp. 109-128. Clifton: Humana Press, 1991.
19. Lappi, D. A., Matsunami, R., Martineau, D., and Baird, A. Reducing the heterogeneity of chemically conjugated targeted toxins: homogeneous basic FGF-saporin. Anal. Biochem., 212: 446-451, 1993.
20. Yu, D., Wolf, J. K., Scanlon, M., Price, J. E., and Hung, M. C. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res., 55: 891-898, 1993.
21. Rosenfeld, M. E., Wang, M., Siegal, G. P., Alvarez, R. D., Mikheeva, G., Krasnykh, V., and Curiel, D. T. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J. Mol. Med., 74: 455-462, 1996.
22. Watkins, S. J., Mesyanzhinov, V. V., Kurochkina, L. P., and Hawkins, R. E. The adenobody approach to viral targeting-specific and enhanced adenoviral gene delivery. Gene Ther., 4: 1004-1012, 1997.
23. Wickham, T. J., Roelvink, P. W., Brough, D. E., and Kovesdi, I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol., 14: 1570-1573, 1996.
24. Wickham, T. J., Segal, D. M., Roelvink, P. W., Carrion, M. E., Lizonova, A., Lee, G. M., and Kovesdi, I. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol., 70: 6831-6838, 1996.
25. Wickham, T. J., Tzeng, E., Shears, L. L., Roelvink, P. W., Li, Y., Lee, G. M., Brough, D. E., Lizonova, A., and Kovesdi, I. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol., 71: 8221-8229, 1997.
26. Elshami, A. A., Cook, J. W., Amin, K. M., Choi, H., Park, J. Y., Coonrod, L., Sun, J., Molnarkimber, K., Wilson, J. M., Kaiser, L. R., and Albelda, S. M. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. Cancer Gene Ther., 4: 213-221, 1997.
27. Yee, D., McGuire, S. E., Brunner, N., Kozelsky, T. W., Allred, D. C., Chen, S-H., and Woo, S. L. C. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum. Gene Ther., 7: 1251-1257, 1996.
28. Jooss, K., Yang, Y., Fisher, K. J., and Wilson, J. M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol., 72: 4212-4223, 1998.
29. Gu, D., Hoganson, D. K., Printz, M., Gonzalez, A. M., Ying, W., Sosnowski, B. A., Curiel, D. T., Pierce, G. F., and Aukerman, S. L. Retargeting adenovirus vectors with FGF-2 leads to enhanced efficacy and decreased toxicity. Proc. Am. Assoc. Cancer Res., 39: 512, 1998.
30. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
31. Rodrigues, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563, 1997.
32. Hallenbeck, P. L., Chang, Y-N., Stewart, D., Hay, C., Golightly, D., and Chiang, Y. L. Novel tumor specific replication restricted adenoviral vector for gene therapy of liver cancer. Cancer Gene Ther., 4: S22, 1997.
33. Dion, L. D., Goldsmith, K. T., Strong, T. V., Bilbao, G., Curiel, D. T., and Garver, R. I., Jr. E1A RNA transcripts amplify adenovirus-mediated tumor reduction. Gene Ther., 3: 1021-1025, 1996.